Successful Treatment With Evocalcet Against Familial Hypocalciuric Hypercalcemia Type 3 (FHH3) Identified by AP2S1 Gene Mutation (p.Arg15Leu)
Conclusion: Evocalcet may be a promising therapeutic candidate for symptomatic FHH3.
Saved in:
Main Authors: | Ai Chida, Yutaka Hasegawa, Toshie Segawa, Daisuke Yamabe, Hirotaka Yan, Yusuke Chiba, Hiraku Chiba, Hirofumi Kinno, Tomoyasu Oda, Yoshihiko Takahashi, Koji Nata, Yasushi Ishigaki |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Case Reports in Endocrinology |
Online Access: | http://dx.doi.org/10.1155/crie/9514578 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A novel frameshift variant of GATA3 (p.Ala17ProfsTer178) responsible for HDR syndrome in a Japanese family
by: Yutaka Hasegawa, et al.
Published: (2024-11-01) -
Four cardiomyopathy patients with a heterozygous DSG2 p.Arg119Ter variant
by: Takuya Sumida, et al.
Published: (2024-12-01) -
The APOA1 p.Leu202Arg variant potentially causes autosomal recessive cardiac amyloidosis
by: Shusuke Yagi, et al.
Published: (2024-08-01) -
Episodic ataxia type 2 with a novel missense variant (Leu602Arg) in CACNA1A
by: Shiroh Miura, et al.
Published: (2024-01-01) -
Missense variants at the p.Arg225 residue in ARHGEF40 identified in individuals with multiple congenital anomalies and developmental delay
by: Melanie P. Napier, et al.
Published: (2025-04-01)